Who
Michael Dybbs
Director
Company insider
Files Form 4 as: Director, Nkarta; Director, Sutro Biopharma; Director, Kalaris Therapeutics; Director, SpyGlass Pharma; Director, Dimension Therapeutics; Director, Versartis.
In numbers
- Trades disclosed
- 32
- Buys
- 1
- Sells
- 0
- Bought
- $12.5M
- Sold
- $0
- Companies
- 6
- Companies where not an officer
- 6
- First trade
- 20 Mar 2014
- Last trade
- 10 Jun 2026
- Last filed
- 11 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 10 Jun 2026filed 11 Jun 2026 | NKTX Nkartaoption or derivative · Biotechnology | SEC FORM 4 Code A | —37,000 at $0.00 | filing |
| 10 Jun 2026filed 11 Jun 2026 | NKTX Nkartaoption or derivative · Biotechnology | SEC FORM 4 Code A | —37,000 at $0.00 | filing |
| 5 Jun 2026filed 9 Jun 2026 | STRO Sutro Biopharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 5 Jun 2026filed 9 Jun 2026 | STRO Sutro Biopharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 3 Jun 2026filed 4 Jun 2026 | KLRS Kalaris Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —9,000 at $0.00 | filing |
| 3 Jun 2026filed 4 Jun 2026 | KLRS Kalaris Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —9,000 at $0.00 | filing |
| 5 Feb 2026filed 9 Feb 2026 | SGP SpyGlass Pharmaoption or derivative · Medical Devices | SEC FORM 4 Code A | —27,400 at $0.00 | filing |
| 5 Feb 2026filed 9 Feb 2026 | SGP SpyGlass Pharmaoption or derivative · Medical Devices | SEC FORM 4 Code A | —27,400 at $0.00 | filing |
| 23 Dec 2025filed 29 Dec 2025 | STRO Sutro Biopharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,500 at $0.00 | filing |
| 6 Jun 2025filed 10 Jun 2025 | STRO Sutro Biopharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 5 Jun 2025filed 9 Jun 2025 | NKTX Nkartaoption or derivative · Biotechnology | SEC FORM 4 Code A | —46,000 at $0.00 | filing |
| 10 Apr 2025filed 11 Apr 2025 | KLRS Kalaris Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —18,000 at $0.00 | filing |
| 13 Jun 2024filed 14 Jun 2024 | NKTX Nkartaoption or derivative · Biotechnology | SEC FORM 4 Code A | —22,500 at $0.00 | filing |
| 6 Jun 2024filed 10 Jun 2024 | STRO Sutro Biopharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —35,000 at $0.00 | filing |
| 8 Jun 2023filed 12 Jun 2023 | STRO Sutro Biopharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
| 7 Jun 2023filed 9 Jun 2023 | NKTX Nkartaoption or derivative · Biotechnology | SEC FORM 4 Code A | —22,500 at $0.00 | filing |
| 8 Jun 2022filed 10 Jun 2022 | NKTX Nkartaoption or derivative · Biotechnology | SEC FORM 4 Code A | —16,000 at $0.00 | filing |
| 6 Jun 2022filed 8 Jun 2022 | STRO Sutro Biopharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —18,500 at $0.00 | filing |
| 13 Jun 2021filed 15 Jun 2021 | NKTX Nkartaoption or derivative · Biotechnology | SEC FORM 4 Code A | —16,511 at $0.00 | filing |
| 3 Jun 2021filed 7 Jun 2021 | STRO Sutro Biopharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —18,500 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.